First, we must maintain the recognition of slow cattle, because only if you recognize that it is a slow bull market, can you insist on holding shares and take more positions at the low position.Second, you must have the patience to hold shares. I told you in early trading that the market in December may be difficult as a whole, not to say that the index risk is great. Under the tone of stabilizing the stock market, there will be no big risk as a whole, but it is uncomfortable for those with high speculation.At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.
Because yesterday, when the mood was the highest, it was inevitable that the turnover would be enlarged. Today, everyone has calmed down, and the volume will drop. Everyone's willingness to trade is not so strong. Some major institutions have done more by themselves. Typically, they don't want everyone to make money.(2) Second, the appreciation of RMB exchange rate is obvious today. Yesterday's trend made everyone dissatisfied, but yesterday's exchange rate performance was very firm. Some people say that the exchange rate strength has anything to do with investors?
Although many people are still pessimistic, I am confident that the trend is bullish. Ups and downs will make many people lose money. Everyone will never make money outside their own cognition. It is better to wait patiently in the direction of their own cognition.(1) First, there was an obvious shrinkage in the opening today. My understanding is that I bought what I should have bought yesterday and sold what I should have sold yesterday. Today, the market has risen, and everyone will not be so impulsive. Therefore, the main funds in the venue are self-directed.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.
Strategy guide
12-13
Strategy guide 12-13
Strategy guide
Strategy guide 12-13
Strategy guide
12-13